-
公开(公告)号：US20140005277A1
公开(公告)日：2014-01-02
申请号：US13720734
申请日：2012-12-19
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Atsuko NAKATA , Eri MATSUMOTO
IPC: A61K47/44
CPC classification number: A61K47/46 , A61K9/0048 , A61K47/02 , A61K47/44
Abstract: This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil and (B) sesame oil. According to the aqueous ophthalmic composition of the present invention, defoaming time is reduced, preservative efficacy is enhanced and photostability is improved.
Abstract translation: 本发明涉及含有（A）聚氧乙烯蓖麻油和（B）芝麻油的水性眼用组合物。 根据本发明的水性眼用组合物，消泡时间降低，防腐效果提高，光稳定性提高。
-
公开(公告)号：US20140005274A1
公开(公告)日：2014-01-02
申请号：US13720799
申请日：2012-12-19
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Atsuko NAKATA
CPC classification number: A61L12/14 , A61K9/0048 , A61K31/07 , A61K31/69 , A61K47/14 , A61K2300/00
Abstract: This invention relates to an aqueous ophthalmic composition comprising (A) polyoxyethylene castor oil in which the number of moles of added ethylene oxide is 2 to 30, and (B) at least one member selected from the group consisting of castor oil and vitamin A. According to the aqueous ophthalmic composition of the present invention, the defoaming time can be reduced even when foam is generated by vibration or impact.
-
公开(公告)号：US20130303626A1
公开(公告)日：2013-11-14
申请号：US13775631
申请日：2013-02-25
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Takayuki MIYANO , Takahiro KUROSE
IPC: A61K47/02
CPC classification number: A61K47/02 , A61K9/0048 , A61K9/08 , A61K31/121
Abstract: An ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent has an advantage that the loss of the geranylgeranylacetone content during long-term storage is very little. This is because of reduced adsorption of geranylgeranylacetone to a wall of an ophthalmic container. The ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent also has an advantage that adsorption of geranylgeranylacetone to a contact lens is little. Further, the ophthalmic composition comprising geranylgeranylacetone and a phosphate buffering agent hardly becomes white turbid even when stored at low temperature.
Abstract translation: 包含香叶基香叶基丙酮和磷酸盐缓冲剂的眼用组合物的优点在于，长期储存期间香叶基香叶基丙酮含量的损失非常小。 这是因为香叶基香叶基丙酮对眼科容器的壁的吸附减少。 包含香叶基香叶基丙酮和磷酸盐缓冲剂的眼用组合物还具有以下优点：香叶基香叶基丙酮对隐形眼镜的吸附少。 此外，即使在低温下储存，包含香叶基香叶基丙酮和磷酸盐缓冲剂的眼用组合物也几乎不变成白色混浊。
-
公开(公告)号：US20250115866A1
公开(公告)日：2025-04-10
申请号：US18832346
申请日：2023-01-20
Applicant: HIROSHIMA UNIVERSITY , ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Masayuki SHIMADA , Takashi UMEHARA , Noriyasu ISHIKAWA , Takashi TAKIJIRI
IPC: C12N5/076
Abstract: The purpose of the present invention is to provide sperm having high motility. The present invention is a composition for treating sperm that comprises medium for mesenchymal stem cells. This composition for treating sperm is used as a sperm preparing solution, a sperm diluting solution, a sperm storage solution, an artificial insemination solution, an in vitro fertilization solution, a solution for improving sperm motility, or a solution for retaining sperm fertilizing capabilities. Additionally, the medium for mesenchymal stem cells contained in the composition for treating sperm is preferably a serum-free medium.
-
公开(公告)号：US12263239B2
公开(公告)日：2025-04-01
申请号：US16958389
申请日：2018-12-27
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Yu Kitaoka , Masatoshi Haga
Abstract: The present invention provides an external composition superior in stability and use feeling. According to the present invention, an external composition is prepared which includes (A) at least one selected from the group consisting of an ascorbic acid and an ascorbic salt, (B) a diol having 3 carbon atoms, (C) at least one selected from the group consisting of a low-molecular-weight betaine, an organic acid salt, an inorganic acid salt, a basic amino acid, a basic amino acid salt, 3-O-ethylascorbic acid, and a 3-O-ethylascorbic acid salt, and (D) water, and a content of ethoxydiglycol of said composition is less than 30 mass %.
-
Patent Agency Ranking
公开(公告)号：US12186264B2
公开(公告)日：2025-01-07
申请号：US17770302
申请日：2019-10-21
Applicant: Rohto Pharmaceutical Co., Ltd.
Inventor： Naohiro Ikeda , Keita Kawai
Abstract: The present invention is a resin container in which an inner wall surface of a container body includes a cyclic olefin copolymer, and a diameter upstream of an outlet of the container body ranges from 0.5 mm to 8.0 mm.
-
公开(公告)号：US11813299B2
公开(公告)日：2023-11-14
申请号：US16614176
申请日：2018-05-15
Applicant: TSUBOTA LABORATORY, INC. , ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Kazuo Tsubota , Toshihide Kurihara
IPC: A61K36/16 , A61P27/10 , A61K9/00 , A61K31/05 , A61K31/202
CPC classification number: A61K36/16 , A61K9/0056 , A61K31/05 , A61K31/202 , A61P27/10
Abstract: The ophthalmic composition effective for the prevention or treatment of myopia or ocular diseases are provided. In particular, the present invention provides an ophthalmic composition effective in a growing child or a young person in whom myopia develops and progresses, as well as a middle-aged and elderly person in whom age-related ocular diseases such as cataract, glaucoma, retinal detachment, retinopathy, maculopathy, choroidal neovascularization, posterior staphyloma, and optic neuropathy develop, a functional food containing the ophthalmic composition, and a screening method capable of searching for the same. [Solution] The above problem is solved by an ophthalmic composition or functional food product containing at least one component selected from the group consisting of crocetin and its pharmaceutically acceptable salts and ginkgo leaf extract.
-
公开(公告)号：US20230330172A1
公开(公告)日：2023-10-19
申请号：US18023119
申请日：2021-08-25
Applicant: NATIONAL UNIVERSITY CORPORATION KUMAMOTO UNIVERSITY , LINK GENOMICS, INC. , ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Hidetaka KATABUCHI , Ritsuo HONDA , Shinichiro NIWA , Eri KITADAI , Hidemi MIZUNUMA , Harumasa ARITA
IPC: A61K36/736 , A61P15/00 , A61K36/899
CPC classification number: A61K36/736 , A61P15/00 , A61K36/899
Abstract: The object of the present invention is to provide: a composition for ameliorating an unpleasant state caused by menstruation, which is effective against discomfort occurring in women in the period from the first menstruation to menopause, particularly strong discomfort occurring in young women, has been sufficiently experienced as a foodstuff and has an anti-EMT activity; and a functional food containing the composition. A composition for ameliorating an unpleasant state caused by menstruation is prepared, which comprises at least one component selected from the group consisting of black rice, cherry blossom, and extracts thereof.
-
公开(公告)号：US11707488B2
公开(公告)日：2023-07-25
申请号：US15755859
申请日：2016-08-29
Applicant: ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Yoshifumi Ikeyama , Hiroyuki Nishida , Tomohiro Tsuda , Eiko Uno , Masayo Yumoto , Kazuma Suda , Mihoko Yoshino , Xuan Trung Ngo
IPC: A61K35/28 , C12N5/0775
CPC classification number: A61K35/28 , C12N5/0662 , C12N2501/998 , C12N2510/00 , Y02A50/30
Abstract: An object of the present invention is to provide novel mesenchymal stem cells demonstrating superior therapeutic effects against various diseases, a novel pharmaceutical composition containing these mesenchymal stem cells, and a method for preparing the same. The present invention relates to ROR1-positive mesenchymal stem cells. The ROR1-positive mesenchymal stem cells are preferably positive for CD29, CD73, CD90, CD105 and CD166 and are derived from umbilical cord or adipose tissue.
-
公开(公告)号：US20230158076A1
公开(公告)日：2023-05-25
申请号：US17918390
申请日：2021-04-09
Applicant: NATIONAL UNIVERSITY CORPORATION TOKAI NATIONAL HIGHER EDUCATION AND RESEARCH SYSTEM , ROHTO PHARMACEUTICAL CO., LTD.
Inventor： Shoichi MARUYAMA , Kazuhiro FURUHASHI , Akihito TANAKA , Munetoshi KARASAWA , Yukinari TAKAO
IPC: A61K35/28 , A61K47/20 , C12N5/0775 , A61P13/12
CPC classification number: A61K35/28 , A61K47/20 , C12N5/0662 , A61P13/12
Abstract: The present invention addresses the problem of providing a fundamental therapeutic method for renal diseases including glomerulonephritis such as IgA nephropathy. To solve this problem, the present invention pertains to an agent for increasing CD25-positive regulatory T cells in kidney, said agent comprising mesenchymal stem cells. The regulatory T cell-increasing agent of the present invention exerts a sufficient therapeutic effect even if further containing a cryopreservation liquid at a concentration of less than 5% (v/v).
-
-
-
-
-
-
-
-
-
Search Results
118
records
(took 0.02 seconds)
